Most recently, we found that DMAPT and/or sulindac in combination with gemcitabine therapy can delay or prevent progression of premalignant pancreatic lesions in the less aggressive LSL-KrasG12D/+; Pdx-1-Cre mouse model of pancreatic cancer [22]. This evidence concerns the gene PDX1 and familial pancreatic carcinoma.